WASHINGTON, May 28, 2013 /PRNewswire-USNewswire/ -- The Bio-Process Systems Alliance (BPSA) is pleased to announce the 3rd annual International Single-Use Summit (ISUS 2013) will be held July 15-17, 2013, in Washington, D.C. The slate of speakers for this year's event will offer insight on the next decade for single-use systems in biopharmaceutical manufacturing, including economics, standardization, workforce challenges, innovation and globalization.
Doug Neugold, Chairman of the Board, CEO and President of ATMI, a global leader in enabling process materials and process technology for semiconductor, display and life science industries, will be the keynote speaker. Neugold will share his perspective on the challenges of innovating and advancing new technologies in a dynamic global economy by drawing from lessons learned in the semiconductor industry.
Ralph S. Tyler, immediate-past chief counsel for the Food and Drug Administration (FDA) who is now with Venable LLP, will talk about what can be expected from the FDA over the next four years, including enforcement, compliance and globalization. In his role with the FDA, Tyler was responsible for the advice and representation of the agency in counseling, litigation and enforcement matters across the product areas within the FDA's jurisdiction.
"Our program committee has succeeded in building a hard-hitting agenda of discussion and commentary on business issues that will impact the rates of adoption and growth of single-use in pharmaceutical manufacture," said Jerold Martin, Senior Vice President of Pall Life Sciences and Chairman of the BPSA board.
Speakers will also share perspectives on Wall Street and the deficit/sequester effect on the U.S. economy and its impact on the biopharmaceutical industry, and experts will examine management challenges evident in today's four generations workplace, specifically the Millennial Generation.
An overview of single-use market trends and the results of the latest Single-Use End User Survey will be presented by BioPlan Associates and Bio-Process International representatives.
A significant portion of the summit agenda will be dedicated to topic panels on particulates, proposed extractable test condition protocols impacting the supplier base, as well as supply chain security. These panels will address definitions, regulations and industry expectations (both user and supplier perspectives) on these key issues, resulting in concrete industry action plans moving forward.
The Bio-Process Systems Alliance (BPSA) was formed in 2005 as an industry-led corporate member trade association dedicated to encouraging and accelerating the adoption of single-use manufacturing technologies used in the production of biopharmaceuticals and vaccines. BPSA facilitates education, sharing of best practices, development of consensus guides and business-to-business networking opportunities among its member company employees. For more information, please visit www.bpsalliance.org, or contact Kevin Ott, Executive Director, at [email protected].
SOURCE Bio-Process Systems Alliance (BPSA)